公开(公告)号：US20240076342A1

公开(公告)日：2024-03-07

申请号：US18187639

申请日：2023-03-21

申请人： UNIVERSITY OF WASHINGTON ,  THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY

发明人： Daniel Adriano Silva Manzano ,  Shawn Yu ,  Umut Ulge ,  David Baker ,  Kenan Christopher Garcia ,  Jamie Spangler ,  Carl Walkey ,  Alfredo Quijano Rubio ,  Kevin Jude ,  Brian Weitzner

IPC分类号： C07K14/55 ,  A61K47/60 ,  A61K47/62 ,  C07K14/54

CPC分类号： C07K14/55 ,  A61K47/60 ,  A61K47/62 ,  C07K14/5406 ,  C07K14/5437 ,  C07K14/5443 ,  A61K38/00

摘要： De novo designed polypeptides that bind to IL-2 receptor βγc heterodimer (IL-2Rβγc), IL-4 receptor αγc heterodimer (IL-4Rαγc), or IL-13 receptor α subunit (IL-13Rα) are disclosed, as are methods for using and designing the polypeptides.

公开(公告)号：US20240075144A1

公开(公告)日：2024-03-07

申请号：US18271364

申请日：2022-01-07

申请人： Emory University ,  Children's Healthcare of Atlanta, Inc.

发明人： Curtis J. Henry ,  Sunil S. Raikar ,  Sarwish Rafiq

IPC分类号： A61K39/00 ,  A61P35/02 ,  C07K14/54 ,  C07K14/55 ,  C07K14/705 ,  C07K14/725 ,  C07K16/28 ,  C12N15/86

CPC分类号： A61K39/464412 ,  A61K39/4611 ,  A61K39/4631 ,  A61K39/4635 ,  A61K39/4636 ,  A61P35/02 ,  C07K14/54 ,  C07K14/55 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70521 ,  C07K16/2803 ,  C12N15/86 ,  A61K2239/38 ,  A61K2239/39 ,  A61K2239/48 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/50 ,  C12N2740/15043

摘要： This disclosure relates to therapeutics containing IL-37, chimeric antigen receptors, nucleic acids, or vectors encoding the same. In certain embodiments, this disclosure relates to methods of treating cancer comprising administering a nucleic acid or vector encoding interleukin-37 to a subject diagnosed with cancer and administering T cells expressing a chimeric antigen receptor to the subject. In certain embodiments, this disclosure relates to methods of treating cancer comprising administering a nucleic acid or vector encoding interleukin-37 and a chimeric antigen receptor to a subject diagnosed with cancer.

公开(公告)号：US20240067690A1

公开(公告)日：2024-02-29

申请号：US18494355

申请日：2023-10-25

申请人： Regeneron Pharmaceuticals, Inc.

发明人： Jiaxi Wu ,  Tong Zhang ,  Samuel Davis ,  Nicolin Bloch

IPC分类号： C07K14/55 ,  A61K38/20 ,  A61K45/06 ,  C07K14/47 ,  C07K14/735 ,  C07K14/74

CPC分类号： C07K14/55 ,  A61K38/2013 ,  A61K45/06 ,  C07K14/4748 ,  C07K14/70535 ,  C07K14/70539 ,  A61K38/00

摘要： This disclosure relates to IL-2 variants and methods of use thereof, including methods of treating or inhibiting a cancer or tumor. The IL-2 variants may have reduced ability in binding to or activating IL-2Rα. The IL-2 variants may retain the ability in binding to or activating IL-2Rβ and/or IL-2Rβγ. In addition, the IL-2 variants may have decreased Treg activity but maintain the capacity to activate NK cells and T effector cells.

公开(公告)号：US20240067689A1

公开(公告)日：2024-02-29

申请号：US18312045

申请日：2023-05-04

申请人： Medicenna Therapeutics, Inc.

发明人： Fahar Merchant

IPC分类号： C07K14/55 ,  A61K38/17 ,  A61K38/20 ,  C07K14/47 ,  C07K14/82 ,  C07K19/00 ,  C12N5/071 ,  C12N15/63

CPC分类号： C07K14/55 ,  A61K38/1761 ,  A61K38/2013 ,  C07K14/4747 ,  C07K14/82 ,  C07K19/00 ,  C12N5/0602 ,  C12N15/63 ,  A61K38/00

摘要： The present invention relates to interleukin-2 fusion proteins. More specifically, the invention provides, in part, fusion proteins that include a interleukin-2 protein moiety joined to a Bcl-2 family member protein moiety.

公开(公告)号：US20240067687A1

公开(公告)日：2024-02-29

申请号：US18501571

申请日：2023-11-03

申请人： DEKA BIOSCIENCES, INC.

发明人： John MUMM

IPC分类号： C07K14/54 ,  A61P35/00 ,  A61P37/06 ,  C07K14/55 ,  C07K16/10 ,  C07K16/28 ,  C07K16/32 ,  C07K16/46

CPC分类号： C07K14/5428 ,  A61P35/00 ,  A61P37/06 ,  C07K14/5406 ,  C07K14/55 ,  C07K16/10 ,  C07K16/1045 ,  C07K16/2803 ,  C07K16/2863 ,  C07K16/2896 ,  C07K16/32 ,  C07K16/464 ,  A61K2039/505 ,  C07K2317/53 ,  C07K2317/565 ,  C07K2317/92

摘要： The application relates to a dual cytokine fusion protein composition, pharmaceutical composition, and/or formulation thereof comprising IL-10 or IL-10 variant molecules fused to a single chain variable fragment scaffolding system and a second cytokine, where the second cytokine is linked in the hinge region of the scFv. The application also relates to methods of using the dual cytokine fusion protein composition for treating cancer, inflammatory diseases or disorders, and immune and immune mediated diseases or disorders.

公开(公告)号：US11896648B2

公开(公告)日：2024-02-13

申请号：US17506483

申请日：2021-10-20

申请人： Gilead Sciences, Inc.

发明人： Manuel Baca ,  Sarah A. Gilmore ,  Hassan Javanbakht ,  Prasenjit K. Mukherjee

IPC分类号： A61K38/20 ,  A61P35/00 ,  A61K39/395 ,  C07K14/55 ,  A61K38/00 ,  A61P31/20

CPC分类号： A61K38/2013 ,  A61K39/3955 ,  A61P31/20 ,  A61P35/00 ,  C07K14/55 ,  A61K38/00 ,  C07K2319/30

摘要： Provided are serum half-life extended-IL-2 variant (IL-2v) heterodimers having reduced binding to the IL2Rα (CD25) subunit. In particular, Fc-IL-2v heterodimers are provided and methods for making and using, e.g. for enhancing an immune response, e.g. in the prevention and treatment of viral infections and cancer.

公开(公告)号：US20240043491A1

公开(公告)日：2024-02-08

申请号：US18258397

申请日：2021-12-21

申请人： MERCK SHARP & DOHME LLC

发明人： Stephen E. ALVES ,  Glareh AZADI ,  Maribel BEAUMONT ,  Lia BENSO ,  Alan C. CHENG ,  Peter GEORGIEV ,  Brian E. HALL ,  Veronica M. JUAN ,  Renee MOORE ,  Venkataraman SRIRAMAN ,  Jie ZHANG-HOOVER

IPC分类号： C07K14/55

CPC分类号： C07K14/55 ,  A61K38/00

摘要： Provided herein are IL-2 muteins that bind to IL-2 receptor subunit but do not have measurable binding to IL-2 receptor subunit. Also provided are compositions, kits, methods, and uses involving such IL-2 muteins.

公开(公告)号：US11866476B2

公开(公告)日：2024-01-09

申请号：US18089754

申请日：2022-12-28

申请人： Xilio Development, Inc.

发明人： Margaret Karow ,  Deborah Moore Lai ,  Dheeraj Tomar ,  Parker Johnson ,  Raphael Rozenfeld ,  Ronan O'Hagan ,  Huawei Qiu

IPC分类号： C07K14/55 ,  A61P35/00 ,  C07K14/54 ,  A61K38/00

CPC分类号： C07K14/55 ,  A61P35/00 ,  C07K14/5443 ,  A61K38/00 ,  C07K2317/52 ,  C07K2317/94 ,  C07K2319/30

摘要： Provided herein are cytokines or functional fragments thereof that, in some embodiments, are engineered to be masked by a masking moiety at one or more receptor binding site(s) of the cytokine or functional fragment thereof. In some embodiments, the cytokines are engineered to be activatable by a protease at a target site, such as in a tumor microenvironment, by including a proteolytically cleavable linker. In some embodiments, the proteolytically cleavable linker links the cytokine to the masking moiety, links the cytokine to a half-life extension domain, and/or links the masking moiety to a half-life extension domain. The masking moiety blocks, occludes, inhibits (e.g., decreases) or otherwise prevents (e.g., masks) the activity or binding of the cytokine to its cognate receptor or protein. Upon proteolytic cleavage of the cleavable linker at the target site, the cytokine becomes activated, which renders it capable of binding to its cognate receptor or protein with increased affinity.

公开(公告)号：US11858996B2

公开(公告)日：2024-01-02

申请号：US16323980

申请日：2017-08-09

申请人： Kymab Limited

发明人： Richard Charles Alfred Sainson ,  Stephen John Arkinstall ,  Jamie Iain Campbell ,  Mohammed Hanif Ali ,  E-Chiang Lee ,  Matthew John McCourt ,  Volker Germaschewski ,  Ian Kirby ,  Miha Kosmac ,  Nahida Parveen ,  Robert Rowlands ,  Gwenoline Borhis

IPC分类号： C07K16/02 ,  A61K39/395 ,  A61P35/00 ,  C07K16/28 ,  A61K47/68 ,  A61K31/282 ,  C07K14/55 ,  C07K16/46 ,  G01N33/50 ,  A61K39/00

CPC分类号： C07K16/2818 ,  A61K31/282 ,  A61K39/395 ,  A61K47/6849 ,  A61P35/00 ,  C07K14/55 ,  C07K16/2827 ,  C07K16/468 ,  G01N33/5026 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/40 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/92

摘要： Antibodies that bind ICOS (Inducible T cell Co-Stimulator). Therapeutic use of anti-ICOS antibodies for modulating the ratio between regulatory T cells and effector T cells, to stimulate the immune system of patients, including use in treating cancers. Methods of producing anti-ICOS antibodies, including species cross-reactive antibodies, using transgenic knock-out mice.

公开(公告)号：US20230416322A1

公开(公告)日：2023-12-28

申请号：US18134016

申请日：2023-04-12

申请人： Cue Biopharma, Inc.

发明人： Ronald D. SEIDEL, III ,  Rodolfo J. CHAPARRO ,  John F. ROSS ,  Chee Meng LOW

IPC分类号： C07K14/495 ,  A61P37/06 ,  C07K14/54 ,  C07K14/545 ,  C07K14/55 ,  C07K14/705 ,  C12N5/00 ,  C12N15/62

CPC分类号： C07K14/495 ,  A61P37/06 ,  C07K14/54 ,  C07K14/5406 ,  C07K14/5412 ,  C07K14/5418 ,  C07K14/5428 ,  C07K14/5443 ,  C07K14/545 ,  C07K14/55 ,  C07K14/70532 ,  C07K14/70575 ,  C12N5/00 ,  C12N15/62 ,  A61K38/00

摘要： The present disclosure provides T-cell modulatory multimeric polypeptides (T-Cell-MMP) and their epitope conjugates comprising at least one immunomodulatory polypeptide (“MOD”) that may be selected to exhibit reduced binding affinity to a cognate co-immunomodulatory polypeptide (“Co-MOD”). The epitope may be, for example, a cancer-associated epitope, an infectious disease-associated epitope, or a self-epitope. The T-Cell-MMP-epitope conjugates are useful for modulating the activity of a T-cell by delivering immunomodulatory peptides, such as IL-2 or IL-2 variants that exhibit reduced binding affinity for the IL-2R, to T-cells in an epitope selective/specific manner, and accordingly, for treating individuals with a cancer, infectious disease or autoimmune disorder.